Free tool
FAERS Monitor: Elucirem
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216986 or its brand name (Elucirem, Gadopiclenol). Reports on generic versions are filed under their own applications.
Reports
278
Serious
100
36% of reports
Hospitalization
30
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- urticaria64
- pruritus45
- nausea42
- vomiting38
- rash28
- erythema20
- anaphylactic reaction17
- dyspnoea17
- hypersensitivity16
- dizziness15
- headache12
- paraesthesia11
- contrast media reaction10
- feeling hot9
- sneezing9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 12 |
| 2024 | 47 |
| 2025 | 121 |
| 2026 | 98 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,881 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| contrast media reactionSignal | 10 | 322.0 | 175.0 | 2,875 |
| sneezingSignal | 9 | 30.4 | 16.0 | 227 |
| urticariaSignal | 64 | 28.9 | 23.3 | 1,710 |
| anaphylactic reactionSignal | 17 | 23.3 | 14.7 | 341 |
| feeling hotSignal | 9 | 11.1 | 5.8 | 73 |
| pruritusSignal | 45 | 8.9 | 6.8 | 312 |
| erythemaSignal | 20 | 7.4 | 4.8 | 105 |
| hypersensitivitySignal | 16 | 6.5 | 4.1 | 70 |
| vomitingSignal | 38 | 6.1 | 4.6 | 161 |
| paraesthesiaSignal | 11 | 5.3 | 3.0 | 34 |
| rashSignal | 28 | 4.9 | 3.4 | 84 |
| nauseaSignal | 42 | 4.0 | 3.0 | 96 |
| dizzinessSignal | 15 | 2.3 | 1.4 | 10 |
| dyspnoeaSignal | 17 | 2.3 | 1.4 | 11 |
| headache | 12 | 1.4 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.